Penicillin G Benzathine (Bicillin L-A) Injection Shortage: Latest Updates and Availability
Areazine synthesizes this FDA drug-shortage notice directly from FDA's official public data feed. See our methodology for full source attribution and refresh cadence.
The FDA reports a current shortage of Penicillin G Benzathine Injection (Bicillin L-A) due to manufacturing delays, with limited availability expected through late 2026.
What this FDA drug-shortage notice tells you, and what most readers miss
This notice was issued by FDA on April 6, 2026 and geographically references United States. Its severity classification of "high" signals how the issuing agency weighs the risk of harm if no action is taken - "critical" and "high" tier alerts typically carry direct consumer actions, while "medium" and "low" tend toward informational guidance or monitoring advisories. The category it belongs to - Drug Shortages - determines the regulatory framework behind it, which shapes what mitigations (alternative therapies, allocation timelines, manufacturer guidance) are available and which agency holds oversight.
Most readers skim a notice like this, check whether they are personally affected, and move on. The more useful lens is to verify its scope, source, and timestamp, then compare related notices without assuming that one record proves a broader trend.
Areazine pairs this record with the original agency URL so you can check the primary source before acting. Its related labels are drug-shortage, fda, medication, Penicillin-G-Benzathine.
What's in Shortage
Penicillin G Benzathine Injection, commonly known by the brand name BICILLIN L-A, is currently in shortage. This medication is classified as an Anti-Infective and is administered as an injection. The shortage was first reported on April 26, 2023, and the status was last updated on February 12, 2026.
Which Manufacturers Are Affected
Pfizer Inc. is the manufacturer currently experiencing supply issues. The status of specific presentations is as follows:
- Bicillin L-A, Injection, 600,000 [iU]/1 mL (NDC 60793-700-10): Currently Unavailable. The manufacturer estimates recovery by December 2026.
- Bicillin L-A, Injection, 1,200,000 [iU]/2 mL (NDC 60793-701-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.
- Bicillin L-A, Injection, 2,400,000 [iU]/4 mL (NDC 60793-702-10): Currently under Limited Availability. The next delivery is expected in July 2026, with an estimated recovery date of December 2026.
For more information, Pfizer Inc. can be contacted at 844-646-4398.
Why There's a Shortage
The manufacturer has cited manufacturing delays as the reason for the current shortage. The FDA database categorizes the reason as "Other."
What Patients Should Do
If you or a loved one depends on this medication, please take the following steps:
- Consult Your Healthcare Provider: Discuss the shortage with your doctor to understand how it may affect your treatment plan.
- Speak with Your Pharmacist: Pharmacists often have the most current information regarding local stock and can help navigate supply issues.
- Contact the Manufacturer: You may reach out to Pfizer Inc. at 844-646-4398 for specific questions regarding their supply timeline.
Disclaimer: Patients should always consult their healthcare provider for medical advice and treatment options. Do not alter your prescribed treatment without professional medical guidance.
Source
Attribution: FDA Drug Shortage Database
Original source: FDA Official Notice ↗
Related Drug Shortages
All Drug Shortages →Frequently Asked Questions
Common questions about this FDA drug-shortage notice.